IDIOPATHIC MEMBANOUS NEPHROPATHY IN SOUTHERN TASMANIA

S KUO1, L JEFFS1,M JOSE1,2, G KIRKLAND1, R YU1, S YEW1
1Royal Hobart Hospital, Hobart, Australia, 2School of Medicine, University of Tasmania, Hobart, Australia

Aim: To describe the incidence, management and outcome of idiopathic membranous nephropathy in Southern Tasmania.
Background: Membranous nephropathy accounts for 20-30% of nephrotic syndrome. Though there is increasing understanding, data in the Tasmanian population remains unknown.
Methods: A retrospective study was performed on patients (>18 years) who had biopsy diagnosed membranous nephropathy in 2007-2017 in Southern Tasmania.
Results: 27 patients (male 71%, median age 58yrs, interquartile range [IQR] 18) were diagnosed with idiopathic membranous nephropathy and 24 have clinical details available.
At diagnosis, the median blood pressure was 145/83mmHg (IQR13/15) with median estimated glomerular filtration rate (eGFR) 50mls/min/1.73m2 (IQR33), albumin creatinine ratio (ACR) 413 g/mol creat (IQR 674), 24-hour urine protein 5.5g/day (IQR4.2) and albumin 26g/L (IQR15). 16 were tested for antibodies to phospholipase A2 receptor and 10 were positive.All patients were commenced on angiotensin inhibition antihypertensive. 10 (42%) were immunosuppressed with alkylating agents, 7 within six months of diagnosis due to severe nephrotic syndrome, delay between symptom onset and biopsy, or severe thrombotic complications. Remission was not achieved in 4 and Rituximab induction was given.20 patients had 1-year follow up with median eGFR of 44 (IQR26) and ACR 115 (IQR190).To date, the median follow-up time is 51months (IQR35). 15 (75%) remains in remission with median eGFR 60 (IQR41) and ACR 22 (IQR92). 8(53%) of those received alkylating agents. One died from unrelated cause, one yet to achieve remission, two relapsed and one progressed to renal failure.
Conclusions: The incidence and long term prognosis of membranous nephropathy in southern Tasmania is comparable to that of international reports.


Biography:
Renal registrar at Royal Hobart Hospital

About ANZSN

The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

© 2015 - 2016 Conference Design Pty Ltd